Add Company
Join Now

Luxa Biotechnology Revenue and Competitors

License our Company Data API

USA

Location

N/A

Total Funding

Pharma

Industry

Employee Data

  • Luxa Biotechnology has 6 Employees.(i)
  • Luxa Biotechnology grew their employee count by 50% last year.

Luxa Biotechnology's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M22116%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M91-10%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M16-6%$114.3MN/A
#8
$7.2M28-7%N/AN/A
#9
$13.7M51-9%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Luxa Biotechnology?

Luxa Biotechnology (LuxaBio) is a clinical-stage biotechnology company developing a novel adult RPE stem cell (RPESC) therapy for dry AMD. The proprietary adult RPESC-derived RPE stem cell product was developed at and licensed from the NSCI. LuxaBio is a partnership between the NSCI research institute and Y2 Solution, a Korean company to evaluate RPESC in a clinical trial to test the safety and efficacy of RPE progenitor stage progeny as a potential therapy for dry AMD. \n\nLuxaBio maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a clinical trial of RPESC-RPE-4W for the Treatment of Dry Age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, Emmes, the University of Michigan Kellogg Eye Center, the National Eye Institute.

keywords:N/A

N/A

Total Funding

6

Number of Employees

N/A

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M6N/AN/A
#2
$0.4M6N/AN/A
#3
$0.4M6N/AN/A
#4
$0.4M6N/AN/A
#5
$0.4M6N/AN/A